Virginia Mason Federal Way Medical Center
Virginia Mason Federal Way Medical Center
Federal Way, Washington, United States26 results ยท Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Not stated | 2026-10-09 | NCT02474160 | |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-02 | NCT02445391 | |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03701282 | |
| Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, ureter cancer, ureteral disorder, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03244384 | |
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, ovarian seromucinous carcinoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-01 | NCT02839707 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Adnexal Diseases, Blood Protein Disorders, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast carcinoma, breast disorder, breast neoplasm, carcinoma, carcinoma of esophagus, cardiovascular disorder, cervical carcinoma, cervix disorder, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, epithelial neoplasm, esophageal disorder, exocrine pancreatic carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric carcinoma, gastric neoplasm, glioma, gonadal disorder, head and neck carcinoma, hematologic disorder, hematopoietic and lymphoid cell neoplasm, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, hepatocellular carcinoma, immune system disorder, immunoproliferative disorder, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung carcinoma, lung disorder, lung neoplasm, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, monoclonal gammopathy, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, ovarian cancer, ovarian carcinoma, ovarian disorder, pancreas disorder, pancreatic neoplasm, plasma cell neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate carcinoma, prostate disorder, rectal carcinoma, rectal disorder, rectal neoplasm, renal carcinoma, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin carcinoma, skin disorder, skin neoplasm, stomach disorder, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, urinary bladder carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine cancer, uterine disorder, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-10-01 | NCT02465060 | |
| Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, metastatic melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02224781 | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Not applicable | 2026-10-01 | NCT02194738 | |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01575548 | |
| Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01272037 | |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Phase 2 | 2026-09-15 | NCT02196181 | |
| Breast Cancer WEight Loss Study (BWEL Study) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, invasive breast carcinoma, neoplasm, skin disorder, synchronous bilateral breast carcinoma | Active, not recruiting | Phase 3 | 2026-09-02 | NCT02750826 | |
| Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-31 | NCT01901094 | |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-28 | NCT03737981 | |
| Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-08-28 | NCT02311933 | |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-28 | NCT02048813 | |
| Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder, vaginal adenocarcinoma, vaginal cancer, vaginal carcinoma, vaginal disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT02466971 | |
| Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-07-02 | NCT02193282 | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Adnexal Diseases, Bartholin gland transitional cell carcinoma, Biliary Tract Neoplasms, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Gestational Trophoblastic Disease, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Nose Neoplasms, Otorhinolaryngologic Neoplasms, Parathyroid Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Pregnancy Complications, Neoplastic, Rare Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acinar cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland pheochromocytoma, angiosarcoma, apocrine sweat gland neoplasm, basal cell carcinoma, basal cell neoplasm, bile duct disorder, bile duct neoplasm, biliary tract disorder, bladder adenocarcinoma, carcinoma, carcinosarcoma, cervical adenocarcinoma, cholangiocarcinoma, chordoma, colorectal squamous cell carcinoma, connective tissue neoplasm, cystadenocarcinoma, cystic, mucinous, and serous neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial transitional cell carcinoma, endometrium neoplasm, epithelial neoplasm, extrahepatic bile duct carcinoma, extramammary Paget disease, fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroma, fibromyxoid tumor, fibrosarcoma, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric squamous cell carcinoma, gastrointestinal stromal tumor, germinoma, gestational trophoblastic neoplasm, gonadal disorder, intrahepatic cholangiocarcinoma, lung adenocarcinoma, lung giant cell carcinoma, lung neoplasm, lung neuroendocrine neoplasm, lung sarcomatoid carcinoma, major salivary gland carcinoma, malignant endocrine neoplasm, minimally invasive lung adenocarcinoma, mixed neoplasm, mouth disorder, mucinous adenocarcinoma, mucinous adenocarcinoma of the appendix, mucinous cystadenocarcinoma, nasal cavity adenocarcinoma, nasal cavity carcinoma, nasal disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, nerve sheath neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, oral cavity carcinoma, otorhinolaryngologic disease, ovarian adenocarcinoma, ovarian cancer, ovarian disorder, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian squamous cell carcinoma, ovarian transitional cell carcinoma, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paraganglioma, paranasal sinus carcinoma, paranasal sinus disorder, paranasal sinus neoplasm, parathyroid gland carcinoma, parathyroid gland disorder, peripheral nervous system disorder, peripheral nervous system neoplasm, pheochromocytoma, placental choriocarcinoma, pregnancy disorder, primitive neuroectodermal tumor, pseudomyxoma peritonei, respiratory system disorder, respiratory tract neoplasm, sarcoma, scrotum squamous cell carcinoma, seminal vesicle adenocarcinoma, seminoma, small intestine adenocarcinoma, somatostatinoma, spindle cell neoplasm, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, testicular non-seminomatous germ cell tumor, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, trachea carcinoma, transitional cell carcinoma, trophoblastic neoplasm, undifferentiated carcinoma of esophagus, undifferentiated carcinoma of nasopharynx, undifferentiated carcinoma of stomach, ureter adenocarcinoma, ureter squamous cell carcinoma, urethra adenocarcinoma, urethra squamous cell carcinoma, vaginal adenocarcinoma, vascular cancer, vulva cancer, vulvar carcinoma, vulvar disease | Active, not recruiting | Phase 2 | 2026-06-17 | NCT02834013 | |
| Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 | Active, not recruiting | Phase 3 | 2026-06-09 | NCT02785952 | |
| Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast adenocarcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-05-06 | NCT02488967 | |
| S0820, Adenoma and Second Primary Prevention Trial | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Active, not recruiting | Phase 3 | 2026-04-02 | NCT01349881 | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-10 | NCT01674140 | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2025-12-19 | NCT02201992 | |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, brain disorder, breast disorder, breast neoplasm, cardiovascular disorder, central nervous system cancer, central nervous system disorder, heart disorder, injury, metastatic malignant neoplasm in the brain, neoplasm, nervous system disorder, radiation injury, skin disorder | Recruiting | Phase 3 | 2025-10-08 | NCT03418961 |